Targeted therapy for HER2 positive breast cancer

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Incorvati, Jason A ^a   Shah, Shilpan ^a   Mu, Ying ^b   Lu, Janice ^a,b  

^a STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

ASCO 2012; Breast cancer; HER2 positive; San Antonio 2012

Indexed keywords

AFATINIB; ANTHRACYCLINE; AROMATASE INHIBITOR; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; MAYTANSINE; NAVELBINE; NERATINIB; PACLITAXEL; PAZOPANIB; PERTUZUMAB; PLACEBO; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

ALOPECIA; ANOREXIA; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CARDIOTOXICITY; CELL DIFFERENTIATION; CELL GROWTH; CELL SURVIVAL; CELLULITIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIMERIZATION; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HAIR COLOR; HAZARD RATIO; HEART DISEASE; HEART LEFT VENTRICLE FAILURE; HUMAN; INFUSION SITE REACTION; LIVER DYSFUNCTION; LIVER ENZYME BLOOD LEVEL; LOADING DRUG DOSE; MEDICAL SOCIETY; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MOLECULAR TARGETED THERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2;

EID: 84878366889     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-38     Document Type: Review

References (56)

1. CDC.gov, Breast Cancer Statistics 2012 http://cdc.gov/cancer/breast/ statistics
2. Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance. Bailey TA, Luan H, Clubb RJ, et al. J Carcinog 2011 10 28 10.4103/1477-3163.90442 22190870
3. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. Graus-Porta D, Beerli RR, Daly JM, Hynes NE, EMBO J 1997 16 1647 1655 10.1093/emboj/16.7.1647 9130710 (Pubitemid 27151960)
4. Treatment of HER2-positive breast cancer: current status and future perspectives. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L, Nat Rev Clin Oncol 2012 9 16 32
5. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Ross JS, Fletcher JA, Oncologist 1998 3 237 252 10388110
6. Prognostic and predictive value of c-erb-B2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J, J Clinical Oncology 1998 16 462 469 (Pubitemid 28135587)
7. Breast cancer outcome and predictors of outcome: are there age differentials? Albain KS, Allred DC, Clark GM, J Natl Cancer Inst Monogr 1994 16 35 42 7999467
8. Transcriptional repression of the neu proto-oncogene by estrogen stimulated estrogen receptor. Russell KS, Hung MC, Cancer Res 1992 52 6624 6629 1358436
9. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. Slamon DJ, Leyland-Jones B, Shak S, et al. N Engl J Med 2001 344 783 792 10.1056/NEJM200103153441101 11248153 (Pubitemid 32222155)
10. HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up. Goldhirsch A, Piccart-Gebhart MJ, Procter M, et al. Cancer Res 2012 72 24 Suppl 103s 104s San Antonio Breast Conference Abstracts 2012
11. PHARE Trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer. Pivot X, Romieu G, Bonnefoi H, et al. Cancer Res 2012 72 24 Suppl 104s San Antonio Breast Conference Abstracts 2012
12. PERSEPHONE: Duration of Trastuzumab with Chemotherapy in women with HER2 positive early breast cancer. Earl HM, Cameron DA, Miles D, et al. Cancer Res 2012 72 24 Suppl 557s 558s San Antonio Breast Conference Abstracts 2012
13. Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831. Romond EH, Suman VJ, Jeong J-H, et al. Cancer Res 2012 72 24 Suppl 105s San Antonio Breast Conference Abstracts 2012
14. Lapatinib: A dual inhibitor of EGFR and HER2 tyrosine kinase activity. Montemurro F, Valabrega G, Aglietta M, Expert Opin Biol Ther 2007 7 257 268 10.1517/14712598.7.2.257 17250463 (Pubitemid 46192173)
15. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. Geyer CE, Forster J, Lindquist D, et al. N Engl J Med 2006 355 2733 2743 10.1056/NEJMoa064320 17192538 (Pubitemid 46021510)
16. Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41. Robidoux A, Tang G, Rastogi P, et al. ASCO Meeting Abstracts 2012 30 LBA506
17. WJOG6110B (ELTOP): Randomized phase II trial comparing trastuzumab plus capecitabine (HX) and lapatinib plus capecitabine (LX) in HER2-positive metastatic breast cancer patients previously treated with trastuzumab and taxanes. Takano T, Kimura H, Nishio K, et al. ASCO Meeting Abstracts 2012 30 TPS659
18. Phase I/II Trial of primary chemotherapy with non-pegylated liposomal doxorubicin, paclitaxel and lapatinib in patients with HER2-positive, early stage breast cancer. Aktas B, Kümmel S, Krocker J, et al. Cancer Res 2012 72 24 Suppl 201s 202s San Antonio Breast Conference Abstracts 2012
19. Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Kodack DP, Chung E, Yamashita H, et al. Cancer Res 2012 72 24 Suppl 341s 342s San Antonio Breast Conference Abstracts 2012
20. Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. Gelmon K, Boyle F, Kaufman B, et al. J Clinical Oncology 2012 30 BA671
21. Molecular effects of lapatinib in HER2 positive ductal carcinoma in situ (DCIS). Estevez LG, Suarez A, Calvo I, et al. Cancer Res 2012 72 24 Suppl 471s San Antonio Breast Conference Abstracts 2012
22. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. Blackwell KL, Burstein HJ, Storniolo AM, et al. J Clin Oncol 2012 30 21 2585 2592 10.1200/JCO.2011.35. 6725 22689807
23. ALTERNATIVE: safety and efficacy of lapatinib (L), trastuzumab (T), or both in combination with an aromatase inhibitor (AI) for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer. Johnston S, Wroblewski S, Huang Y, et al. Cancer Res 2012 72 24 Suppl 558s San Antonio Breast Conference Abstracts 2012
24. A phase III randomized study of Paclitaxel and Trastuzumab versus Paclitaxel, Trastuzumab and Lapatinib in first line treatment of HER2 positive metastatic breast cancer. Crown JP, Moulton B, O'Donovan N, et al. Cancer Res 2012 72 24 Suppl 559s San Antonio Breast Conference Abstracts 2012
25. Human epidermal growth factor receptor 2 (HER2) suppression with the addition of lapatinib to trastuzumab in HER2-positive metastatic breast cancer (LTP112515). Lin N, Danso MA, David AK, et al. Cancer Res 2012 72 24 Suppl 559s San Antonio Breast Conference Abstracts 2012
26. HER2 therapy-an abundance of riches. Gradishar WJ, N Engl J Med 2012 366 2 176 178 10.1056/NEJMe1113641 22149874
27. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomized multicentre, open-label, phase 2 trial. Gianni L, Pienkowski T, Im YH, et al. Lancet Oncol 2012 13 25 32 10.1016/S1470-2045(11) 70336-9 22153890
28. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. Baselga J, Cortes J, Kim S-B, et al. N Engl J Med 2012 366 109 119 10.1056/NEJMoa1113216 22149875
29. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival from a randomized, double-blind, placebo-controlled, phase III study. Swain S, Kim S-B, Cortes J, et al. Lancet Oncol 2013 Published Online: 18 April 2013
30. A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer 2012 http://www.ibcsg.org/Public/Health-Professionals/ Open-Trials/IBCSG-39-11/Pages/IBCSG39-11BIG4-11-APHINITY.aspx
31. A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2-positive metastatic breast cancer: An open-label, two-cohort, phase II study (VELVET). Perez EA, Lopez-Vega JM, Del Mastro L, et al. ASCO Meeting Abstracts 2012 30 TPS653
32. Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: A randomized phase II study (PERTAIN). Rimawi MF, Poole CJ, Ferrero J-M, et al. ASCO Meeting Abstracts 2012 30 TPS654
33. Biomarker analyses in CLEOPATRA: A phase III, placebo, controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC). Baselga J, Cortés J, Im S-A, et al. Cancer Res 2012 72 24 Suppl 103s San Antonio Breast Conference Abstracts 2012
34. Pertuzumab (P) in combination with trastuzumab (T) and docetaxel (D) in elderly patients with HER2-positive metastatic breast cancer in the CLEOPATRA study. Miles D, Baselga J, Amadori D, et al. Cancer Res 2012 72 24 Suppl 464s 465s San Antonio Breast Conference Abstracts 2012
35. A single-arm phase IIIb study of pertuzumab and trastuzumab with a taxane as first-line therapy for patients with HER2-positive advanced breast cancer (PERUSE). Bachelot T, Ciruelos E, Peretz-Yablonski T, et al. Cancer Res 2012 72 24 Suppl 557s San Antonio Breast Conference Abstracts 2012
36. Gavilá J, Llombart A, Guerrero A, et al. Opti-HER HEART: A prospective, multicenter, single-arm, phase II study to evaluate the safety of neoadjuvant liposomal doxorubicin plus paclitaxel, trastuzumab, and pertuzumab in patients with operable HER 2-positive breast cancer San Antonio Breast Conference Abstracts. 2012 560s 561s
37. Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, Guardino E, Song C, Tong B, Ng V, Chu YW, Perez EA, J Clin Oncol 2013 31 1157 63 10.1200/JCO.2012.44.9694 23382472
38. Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. Verma S, Miles D, Gianni L, Krop I, Welslau M, Baselga J, Pegram M, Oh D, Dieras V, Guardino E, Fang L, Lu M, Olsen S, Blackwell K, N Engl J Med 2012 367 1783 1791 10.1056/NEJMoa1209124 23020162
39. ClinicalTrials.gov [Internet], Bethesda (MD): National Library of Medicine (US). 2010 April 28. Identifier NCT01120184, A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE) 2010 http://clinicaltrials.gov/show/NCT01120184
40. Pharmacokinetics and exposure-efficacy relationship of trastuzumab emtansine in EMILIA, a phase 3 study of trastuzumab emtansine vs capecitabine and lapatinib in HER2-positive locally advanced or metastatic breast cancer. Wang B, Jin J, Wada R, et al. Cancer Res 2012 72 24 Suppl 469s 470s
41. A randomized phase II study (VEG108838) of lapatinib plus pazopanib (L + P) versus lapatinib (L) in patients with ErbB2+ inflammatory breast cancer (IBC). Cristofanilli M, Johnston SRD, Manikhas A, et al. ASCO Meeting Abstracts 2012 30 531
42. A neoadjuvant, randomized, open-label phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC). Rimawi MF, Aleixo SB, Alarcon Rozas A, et al. ASCO Meeting Abstracts 2012 30 606
43. Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Tsang RY, Finn RS, Br J Cancer 2012 106 6 13 10.1038/bjc.2011.516 22215104
44. LUX-breast 1: Randomized, phase III trial of afatinib and vinorelbine versus trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment. Harbeck N, Im S-A, Huang C-S, et al. ASCO Meeting Abstracts 2012 30 TPS649
45. LUX-breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatinib (L). Hickish T, Tseng L-M, Mehta AO, et al. ASCO Meeting Abstracts 2012 30 TPS651
46. LUX-breast 3: Randomized phase II study of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients (pts) with HER2-positive breast cancer (BC) with progressive brain metastases (BM) after trastuzumab or lapatinib-based therapy. Joensuu H, Ould KM, ASCO Meeting Abstracts 2012 30 TPS647
47. Cromer J,89 study group. Open-label, phase II trial of afatinib, with or without vinorelbine (V), for the treatment of HER2-overexpressing inflammatory breast cancer (IBC). ASCO. Swanton C, Meeting Abstracts 2012 30 TPS650
48. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Rabindran SK, et al. Cancer Res 2004 64 3958 65 10.1158/0008-5472.CAN-03-2868 15173008 (Pubitemid 38697310)
49. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. Burstein HJ, et al. J Clin Oncol 2010 28 1301 7 10.1200/JCO.2009.25.8707 20142587
50. ClinicalTrials.gov [Internet], Bethesda (MD): National Library of Medicine (US). 2009 April 8. Identifier NCT00878709, Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer (ExteNET) 2009 http://clinicaltrials.gov/show/NCT00878709
51. Effect of neratinib (N) alone and in combination with trastuzumab (T) in HER2-positive breast cancer (BC) cell lines. Canonici A, Pedersen K, Walsh N, Crown J, O'Donovan N, ASCO Meeting Abstracts 2012 30 632
52. A phase I dose-escalation study evaluating weekly paclitaxel with neratinib and trastuzumab in women with metastatic HER2-positive breast cancer, NSABP FB-8. Jankowitz RC, Abraham J, Tan AR, et al. ASCO Meeting Abstracts 2012 30 611
53. Freedman RA, Gelman RS, Wefel JS, et al. TBCRC 022: Phase II Trial of Neratinib for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast cancer and Brain Metastases San Antonio Breast Conference Abstracts. 2012 561s 562s
54. Targeted therapies for breast cancer. Higgins MJ, Baselga J, J Clin Investig 2011 121 3797 3803 10.1172/JCI57152 21965336
55. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Bose R, Kavuri SM, Searleman AC, et al. Cancer Discov 2013 3 2 224 37 10.1158/2159-8290.CD-12-0349 23220880
56. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells. Hu C, Huang L, Xi X, et al. J Hematol Oncol 2012 5 16 10.1186/1756-8722-5-16 22534171